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Abstract
Objective—To estimate the potential health impact and cost-effectiveness of nationwide 
Haemophilus influenzae type b (Hib) vaccination in India.
Study design—A decision support model was used, bringing together estimates of demography, 
epidemiology, Hib vaccine effectiveness, Hib vaccine costs, and health care costs. Scenarios 
favorable and unfavorable to the vaccine were evaluated. State-level analyses indicate where the 
vaccine might have the greatest impact and value.
Results—Between 2012 and 2031, Hib conjugate vaccination is estimated to prevent over 200 
000 child deaths (~1% of deaths in children <5 years of age) in India at an incremental cost of US
$127 million per year. From a government perspective, state-level cost-effectiveness ranged from 
US$192 to US$1033 per discounted disability adjusted life years averted. With the inclusion of 
household health care costs, cost-effectiveness ranged from US$155-US$939 per discounted 
disability adjusted life year averted. These values are below the World Health Organization 
thresholds for cost effectiveness of public health interventions.
Conclusions—Hib conjugate vaccination is a cost-effective intervention in all States of India. 
This conclusion does not alter with plausible changes in key parameters. Although investment in 
Hib conjugate vaccination would significantly increase the cost of the Universal Immunization 
Program, about 15% of the incremental cost would be offset by health care cost savings. Efforts 
should be made to expedite the nationwide introduction of Hib conjugate vaccination in India.
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During the last decade 1 in every 10 children born in India died before reaching their fifth 
birthday, representing around 20% of child deaths globally.1 A nationally representative 
mortality survey conducted in India between 2001 and 2003 (the “Million Death Study”) 
estimated that 16% of deaths of children <5 years of age were caused by pneumonia and 
~4% by invasive bacterial diseases such as meningitis.2 Haemophilus influenzae type b 
(Hib), a bacterium transmitted from person to person by the respiratory route, is a leading 
cause of bacterial pneumonia in countries where the vaccine is not used. Safe and effective 
national Hib conjugate vaccination programs are now implemented in most countries 
worldwide, but introduction has been delayed considerably in India compared with other 
countries. In June 2008, the Indian National Technical Advisory Group on Immunization 
recommended nationwide introduction of Hib conjugate vaccination.3,4 It subsequently took 
3.5 years to initiate phased introduction, starting in December 2011 with Tamil Nadu and 
Kerala, 2 states covering less than 5% of the national child mortality burden. To date, the 
vaccine is yet to be introduced in any of the high mortality states.
Several challenges have contributed to the delayed introduction. In particular, there has been 
a lack of technical consensus on the public health need and cost-effectiveness of including 
the vaccine in the national immunization program. In July 2005, a pilot Hib disease 
surveillance study was initiated to lay the groundwork for a large vaccine probe study to 
document the burden of Hib disease in India and the impact of vaccination.5 The probe study 
was, however, never conducted, as it was judged unethical following a World Health 
Organization (WHO) position that “conjugate Hib conjugate vaccines should be included in 
all routine infant immunization programs.”6 Also, at this time, Hib conjugate vaccines 
became widely available in the private sector in India and several Indian manufacturers were 
producing the vaccine. The only randomized controlled trial in Asia (Lombok Island, 
Indonesia; 1998–2002) reported a preventable incidence of both clinical pneumonia (1561 
per 100 000 aged <2 years) and meningitis (16 per 100 000 aged <2 years). Confusingly, 
however, the same study reported no preventable burden of radiologic pneumonia.7 A case 
control study (Dhaka city, Bangladesh; 2000–2003) reported a 32% protective effect against 
radiologic pneumonia. However, results from this study varied considerably depending on 
who read the chest radiographs and whether the controls were hospital- or community-based 
(16%–44%).8 The mixed evidence from the region and the lack of strong evidence from 
India have made it difficult for country officials to make a decision about Hib conjugate 
vaccination, and some local groups have argued against its inclusion in the routine program.9 
Where uncertainties exist and are likely to continue to exist, decision support models can 
help decision makers consider the potential impact and cost-effectiveness of the vaccine 
under a range of plausible favorable, and more importantly, unfavorable, assumptions.
In this analysis, a decision support model was used to bring together the best available 
evidence and calculate, for a broad range of scenarios, the impact and value (cost-
effectiveness) of Hib conjugate vaccination in India. We estimated this for individual states 
and aggregated to the national level over the period 2012–2031. With an annual birth cohort 
of ~26 million, the Ministry of Health and Family Welfare has to consider very carefully the 
economic implications of universal Hib conjugate vaccination. The aim of cost-effectiveness 
analysis is to help decision-makers make investments in health interventions, which provide 
good value for money when compared with recognized benchmarks or competing health 
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priorities. This study estimate, the potential cost-effectiveness of nationwide Hib conjugate 
vaccination in India.
Methods
The decision-support model has been described in detail elsewhere.10 In short, the model 
tracks the experience of 20 successive birth cohorts. Cost-effectiveness is based on the 
aggregated costs and benefits over this sustained period of routine vaccination (2012–2031) 
allowing key parameters to vary over time. Vaccination program costs are assumed to occur 
in the first year of each cohort. Disease cases, deaths, and treatment costs are estimated for 
the first 5 years of age, but lost life-years, disability adjusted life years (DALYs), and 
sequelae costs are estimated over expected lifetimes. State-level estimates of numbers of 
births, infant mortality, mortality of children <5 years of age, and life-expectancy were based 
on the 2001 census projections.11 State-level estimates of numbers of births were scaled to 
be consistent with the national United National Population projections (2008 Revision) for 
India.1 Estimates of neonatal mortality for each state were based on the 2005–2006 Indian 
National Family Health Survey (NFHS).12 Hib disease is divided into 3 categories defined 
by the Hib global burden of disease project13: pneumonia, meningitis, and “non-pneumonia-
non-meningitis” (NPNM) invasive diseases. NPNM diseases, such as cellulitis and 
epiglottitis, were grouped for simplicity because they are less common than meningitis and 
pneumonia. The model structure is shown in Figure 1. Outputs are compared with a scenario 
with no Hib conjugate vaccination. The analysis was undertaken from a societal perspective, 
including costs incurred by the Indian Government, the GAVI Alliance, and Indian 
households. Future program costs, treatment costs averted, and health benefits were 
discounted by 3% per year.14 We did not assume age weighting on DALYs (ie, no greater 
preference was assigned to life-years gained in the working age range). Costs were estimated 
in 2010 US$ using an exchange rate of 45.7 Indian rupees for one US$.15
Cases of Hib Meningitis, Deaths, and Sequelae
Between 1997 and 1999, a prospective hospital surveillance study in Vellore reported Hib to 
be the cause of 44% (8 of 18) of confirmed cases of bacterial meningitis, with ~7 confirmed 
cases per 100 000 children aged less than 5 years.16 Recent multicenter surveillance 
estimates from Vellore, Chennai, Lucknow, and New Delhi suggest that 70% of bacterial 
meningitis may be caused by Hib.17 We used the lower and more conservative estimate of 
44%, but made adjustments to account for cases of Hib that were not detected in the 
laboratory and cases that did not have access to care. Because 57% (24 of 42) of the purulent 
(probable) cases had no confirmed pathogen in the Vellore study, we assumed the percent of 
unconfirmed cases attributable to Hib to be the same as the percent of confirmed cases 
attributable to Hib (44%), based on WHO guidelines 18 and following methods used in other 
bacterial meningitis etiology studies.19 In addition, we assumed that 23% of the cases would 
not have had access to formal medical care during this study based on the proportion of 
children living in Vellore who, according to the NFHS, did not seek care for acute lower 
respiratory infection (ALRI) in 2006.12 Hence, the final adjusted Hib meningitis incidence 
was 22 per 100 000 children <5 years [7.12/(1–57%)]/(1–23%). We assumed this incidence 
estimate for all states.
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State-level Hib meningitis case fatality ratios (CFRs) were calculated by adjusting the 11% 
CFR reported in multicenter bacterial surveillance sites in Chennai, Vellore, Lucknow, and 
New Delhi17 by the state-level proportion of children without access to medical care. For 
children with no access to care, a 100% CFR was assumed.10 State-level estimates of access 
to care were based on the NFHS 2006 survey with care seeking for ALRI considered to be a 
proxy for meningitis. The median state-level estimate of access to a medical provider was 
71% and ranged from 44%–89% across the states.12 After adjusting for access to care, the 
median meningitis CFR was 36% and ranged from 21%–61% across states.
A proportion of survivors of Hib meningitis suffer lifelong disabilities. Studies reporting the 
risk of sequelae following bacterial meningitis have been conducted in Chandigargh,20 
Kerala,21 Varanasi,22 Hyderabad,23 and Pune.24 Hib-specific data were presented in 3 of the 
studies,20,23,24 but the study in Hyderabad only assessed hearing deficit and, therefore, was 
excluded. The pooled risk of major sequelae following Hib meningitis from the 2 remaining 
studies in Pune (5 of 13) and Chandigarh (4 of 13) was 35%.20,24 These proportions are 
similar to the proportion of children who suffered sequelae in the US and other countries 
prior to the use of Hib conjugate vaccines.
Cases of Hib Pneumonia and Deaths
Various studies of clinical pneumonia incidence have been conducted among children aged 
less than 5 years at the community-level in India. In these studies, the incidence per child per 
year was reported to be 0.54 (Haryana),25 0.29 (Pune),26 0.86 (Rajasthan),27 0.31 (Delhi),28 
0.07 (Maharastra),29 0.10 (Lucknow),30 0.4 (Tripura),31 0.67 (Delhi),32 and 0.53 
(Karnataka).33 These studies vary in terms of geographical location, study design, period of 
reporting, and definition of ALRI. We assumed the IQR from all reported estimates to give a 
plausible national range (ie, 0.29–0.54 episodes per child per year). This is broadly 
consistent with previous estimates for India.34
We assumed that the fraction of ALRI caused by Hib would be equal to the fraction of ALRI 
prevented by Hib conjugate vaccination (3.8%) in the only randomized controlled trial 
conducted in Asia (Lombok Island, Indonesia).7 The IQR of Hib pneumonia incidence was 
therefore 1102 (3.8% × 29 000) to 2052 (3.8% × 54 000) per 100 000 children <5 years of 
age. The state-level distribution of Hib pneumonia incidence was assumed to be the same as 
the state-level distribution for the prevalence of underweight children,12 a consistently 
reported risk factor for pneumonia in India.35,36 Underweight children have weight-for-age 
that is 2 or more SDs lower than the median weight-for-age of an international reference 
population, which includes healthy children from Brazil, Ghana, India, Norway, Oman, and 
the US.37
Regional estimates of the proportion of mortality of children <5 years of age caused by 
pneumonia in children aged 1–59 months were reported in the Million Death Study: West 
(13%); South (8%); East (18%); North (15%); Northeast (16%); and, Central (17%).2 These 
were multiplied by total deaths in children <5 years of age in each state to estimate 
pneumonia deaths in this age group.
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The fraction of pneumonia deaths in children aged 1–59 months caused by Hib is a 
contentious parameter and an important driver of cost-effectiveness results.10 We derived 
this fraction by combining: (1) state-level estimates of Hib pneumonia incidence described 
above; (2) recent multisite estimates of hospitalised pneumonia incidence and CFRs, 
extrapolated to parent regions5; and (3) state-level estimates of access to medical care from 
the 2005–2006 NFHS survey.12 We further assumed a 23.6% CFR for all severe untreated 
pneumonia based on a community-based trial among children 0–4 years in Gadchiroli, 
central India.38 Using this approach (Figure 2), we estimated 7% of pneumonia deaths in 
children aged 1–59 months to be caused by Hib nationally, ranging from 1%–11% across 
states. The 7% estimate is broadly consistent with the pooled 5% reduction in radiologic 
pneumonia found when combining the results from the only 2 Hib conjugate vaccine studies 
conducted in Asia. Using inverse variance meta-analysis, 64% weight was assigned to the 
randomized controlled trial in Indonesia (vaccine effectiveness –10%; 95% CI −33%, 9%) 
and 36% weight to the case control study in Bangladesh (vaccine effectiveness 32%; 95% CI 
−2%, 54%).39 This pooled estimate is, however, subject to large heterogeneity (I-squared 
82%) and is far lower than previously reported global estimates. We, therefore, evaluated a 
separate scenario assuming Hib to be the cause of 20% of pneumonia deaths 1–59 months 
across all states. The Hib global burden of disease project estimated 21% globally in 
children aged 1–23 months based on a global meta-analysis using studies from Bangladesh, 
Indonesia, Chile, and The Gambia.13 This is similar to the fraction reported by a hospital 
etiology study conducted in New Delhi around 20 years ago. In this study, Hib was 
estimated to be the cause of 19% (21 of 110) of hospitalized pneumonia in children <5 
years,40 although the study did not define whether the positive results of latex agglutination 
were found in urine (lower validity) or serum (higher validity). Two other studies from New 
Delhi and Chandigarh, estimated Haemophilus influenzae to be the cause in 16% (20 of 
122)41 and 13% (6 of 46)42 of hospitalized pneumonia cases respectively, but did not 
distinguish type b from nontypeable or other Haemophilus influenzae types.
Cases of Hib NPNM and Deaths
In the multicenter Invasive Bacterial Infections Surveillance Project (Chennai, Lucknow, 
Nagpur, New Delhi, Thiruvananthapuram, Vellore) one case of invasive NPNM Hib disease 
was confirmed for every 5.5 cases of Hib meningitis.43 We applied this ratio to the 
meningitis incidence rate to derive an NPNM incidence rate of 4 per 100 000 children <5 
years of age. We assumed 4.3% CFR for those with access to medical care based on the CFR 
reported by the Invasive Bacterial Infections Surveillance Project for Hib-positive cases 
without associated meningitis. We doubled the CFR for children without access to medical 
care (8.6%), but this conservative assumption is likely to underestimate the true mortality 
burden for invasive NPNM diseases. The adjusted state-level CFRs ranged from 5%–7%.
Please see Table I for a full summary of the disease burden parameters used for each state.
Health Care Utilization
For cases of Hib meningitis and Hib NPNM, we assumed that children with access to 
medical care would be admitted to hospital and also have 1 outpatient consultation, either as 
a referral or follow-up visit. For all cases of pneumonia, we assumed 1 outpatient visit per 
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case for those with access to medical care and that a fraction of these would also be admitted 
to hospital. Severe clinical hospitalized pneumonia per 100 000 per year in children aged <2 
years was recently reported in Chandigarh (2717), Vellore (3075), and Kolkata (7890). To 
avoid over-estimation of incidence, we converted incidence at age <2 years into incidence at 
age <5 years using national age distribution assumptions. We then used state-level estimates 
of clinical pneumonia incidence at age <5 years and access to medical care to calculate the 
fraction of cases with access to medical care who were hospitalized. We estimated that 3%, 
6%, and 13% were hospitalized in each of the 3 sites. On this basis, we assumed 3% for all 
North and North Eastern States, 6% for the South and Western States, and 13% for the 
Central and Eastern States. We further assumed that these all-cause pneumonia fractions 
would apply to Hib pneumonia, to give median state-level incidence of admissions of 55 per 
100 000 per year among children aged <5 years, ranging from 22–185 across states.
Health Service Costs
Costs for outpatient care differed according to whether the child was taken to a public or 
private facility, a traditional healer, or whether only drugs were purchased at a pharmacy. 
Costs for inpatient admissions varied with the level and type of hospital. The NFHS was 
used to estimate the proportion of children accessing each type of provider according to 
State (Table II).12 The NFHS only includes a primary and a secondary/tertiary hospital level 
category for the public sector. To account for differences in costs between secondary and 
tertiary levels, we crudely assumed that tertiary-level care accounted for 5% of the reported 
visits/admissions in the combined secondary/tertiary category.
Treatment cost estimates are summarized in Table III. Two published sources were used. 
Household expenses were collected from the 60th round of the Government of India 
National Sample Survey Organization socioeconomic survey, conducted in 2004.44 
Questions on morbidity and health care were incorporated in the survey, including detailed 
questions about medical expenditures according to type of disease. Information was 
collected for every inpatient admission and outpatient visit for each member of the sample 
household during the 365 and 15 days preceding the survey, respectively. Household 
expenditures were categorized according to medicines, user fees, lodging, transport, etc. 
Results of the survey on respiratory ailments in children <5 years old were used for 
approximating household costs of pneumonia treatment. For this disease category, the 
nationwide sample sizes were 644 outpatient episodes and 238 inpatient admissions. The 
cost of a traditional healer consultation was assumed to be one-half the cost of a public 
sector clinic visit.
To estimate household costs of meningitis treatment, the pneumonia costs were adjusted 
upwards in accordance with the additional lengths of stay in hospital as reported in 
multicenter surveillance in Lucknow, Chennai, Vellore, and New Delhi in preparation for the 
Hib probe study.5 This was 6 days for pneumonia/NPNM and 10 days for meningitis. 
Opportunity costs, in terms of time spent while looking after a sick child, were included in 
the sensitivity analysis by assuming the minimal wage rate of US$3.4 per day,45 multiplied 
by the average length of stay in hospital. There is no empirical evidence from India on the 
costs of treating a case of sequelae or the life-time earnings lost because of caring for a child 
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with permanent disability, so we did not include sequelae costs in the base case. However, in 
a scenario analysis based on a recent sequelae costing study from Senegal, we assumed 
undiscounted lifetime costs of US$53 165 per child with sequel.46 To allow discounting of 
future costs, these costs were converted into annual costs spread over the entire life 
expectancy of each state.
Government costs of meningitis and pneumonia treatment were derived from a micro-
costing study by Krishnan et al undertaken in the State of Haryana in children aged <5 
years.47,48 Data were collected from 2 primary health centers, 6 secondary hospitals, and 2 
tertiary hospitals; 6 of these were government facilities and 2 were private. Another study on 
costs of severe pneumonia from 2 non-government organization hospitals in Vellore was 
used as a comparator.49
Age Distributions and DALY Estimates
The age distribution of Hib disease also was derived from the multicenter surveillance study. 
Among children <2 years of age with confirmed Hib disease, 24% were aged <3 months, 
20% 3–5 months, 21% 6–8 months, 11% 9–11 months, and 23% 12–23 months old.5 We 
assumed that 6% of children <5 years of age would occur between 24 and 59 months,50 so 
proportions for <24 months were adjusted accordingly.
The original DALY formula and disability weights of 0.279 for pneumonia and 0.616 for 
meningitis were used.51 Because there are no standard disability weights available for any of 
the NPNM diseases, the pneumonia weight was used. The weighted average disability 
weight for meningitis sequelae was 0.34 based on the reported global distribution of 
sequelae syndromes52 and their respective disability weights.51 The most common types of 
single sequela from Hib meningitis are hearing loss and seizures, comprising 33% and 16% 
of sequelae cases, respectively. Multiple sequelae are seen in approximately 20% of sequelae 
cases.52
Vaccine Coverage and Efficacy
To account for gradual or phased Hib conjugate vaccine introduction, we assumed 50% and 
75% of diphtheria-tetanus-pertussis (DTP) coverage levels in the first 2 years and full DTP 
coverage thereafter. Coverage of the first 3 doses of DTP were based on the 2009 State-
Level Coverage Evaluation Survey.53 In the base case, we assumed no improvement in 
coverage over time, but this assumption was varied in scenario analysis to allow for annual 
improvements (reductions in the unvaccinated) over the period 2012–2030. Many children 
do not receive their vaccines according to the recommended 6-, 10-, and 14-week schedule. 
We, therefore, estimated the timeliness of vaccination (age-specific coverage) for each state 
using previously described methods.54
Simple multiplication of vaccine efficacy and vaccine coverage is likely to overestimate the 
impact of vaccination because children who receive the vaccine may not be at the highest 
risk of mortality. To account for this relative coverage effect, we estimated DTP2 coverage 
of underweight children relative to the total DTP2 coverage reported for the cohort,12 the 
implication being that underweight children are likely to be at higher risk of death, and that 
DTP2 would broadly represent the relative coverage for all three doses. Relative coverage 
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multipliers (coverage in underweight children divided by coverage in the cohort) were 
calculated for each State (Figure 3).
To estimate the percent reduction in disease, the base case estimates accounted for state-
level timeliness of vaccination, dose-specific coverage, and relative coverage. Vaccine 
efficacy was determined from a recent meta-analysis of controlled clinical Hib conjugate 
vaccine trials. In this analysis, efficacy against all forms of invasive Hib disease was 93% 
(95% CI 83%, 97%) following 3 doses, 92% (95% CI, 69%, 98%) following 2 doses, and 
59% (95% CI 0%, 86%) following 1 dose.55
Herd immunity and waning dose protection were not considered in the base case, but were 
included in scenarios. We assumed that vaccine protection could wane at a fixed rate of up to 
5% per year, and that herd immunity could increase overall impact by up to 20%.56
Hib Conjugate Vaccine Cost Assumptions
Four Indian companies produce and market Hib conjugate vaccine: Serum Institute of India 
(Pune), Panacea Biotec (New Delhi), Bharat Biotech (Hyderabad), and Biological E 
(Hyderabad). The presentations are monovalent Hib conjugate vaccine and Hib combined 
with DTP and hepatitis B vaccines (“pentavalent vaccine”). Although Indian vaccine 
procurement is normally processed between the government and the manufacturers directly, 
Global Alliance for Vaccines and Immunization Alliance funded vaccines are purchased 
through United Nations Children’s Fund, which only accepts WHO prequalified vaccines. 
The vaccine used in Tamil Nadu and Kerala is the 10-dose vial pentavalent vaccine produced 
by Serum Institute of India procured at a United Nations Children’s Fund price of US$1.75 
per dose.57 For the base case we assumed a cost of $1.82 per dose (including 4% tax) and no 
decline in dose price over time. A declining price trend was evaluated in scenario analysis.
When estimating the incremental costs of Hib conjugate vaccine, we calculated the cost 
difference between a schedule with pentavalent vaccine and with DTP and hepatitis B 
vaccines. Phased introduction of monovalent hepatitis B vaccine in a 10-dose vial started in 
2002 with nationwide uptake in 2011. The 2010 prices per dose of DTP and hepatitis B 
vaccines were US$0.04 and US$0.11, respectively.58 Because a 10-dose pentavalent vaccine 
vial is used, there is no need to allow for cold chain expansion.
Uncertainty Analysis
First, we varied each parameter in turn by ±10% to establish the parameters with the greatest 
influence on the cost-effectiveness results (univariate 1-way sensitivity analysis). Second, we 
ran 19 alternative scenarios (10 favorable and nine unfavorable) to evaluate how sensitive the 
results were when we changed combinations of influential parameters (multivariate scenario 
analysis) (eg, given the uncertainty around the incidence of Hib disease in India), the most 
unfavorable scenario assumed a dramatically reduced incidence rate for both Hib pneumonia 
(50% of the base value) and Hib meningitis (32% of the base value) combined with several 
other unfavorable assumptions.
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Results
Hib Conjugate Vaccine Impact
Between 2012 and 2031, Hib conjugate vaccination is estimated to prevent 207 859 
undiscounted child deaths (<1% of deaths in children <5 years of age) assuming no benefit 
from herd immunity. Undiscounted lives saved were 127 869 for Hib pneumonia, 77 840 for 
Hib meningitis, and 2150 for Hib NPNM. The median reduction in total deaths of children 
<5 years of age was 0.9% and ranged from 0.3%–2.0% across states (Table IV and Figure 
4).
Hib Conjugate Vaccine Program Costs
The incremental costs of introducing Hib conjugate vaccination would be approximately US
$127 million per year based on current vaccine prices (Table V). Without Hib conjugate 
vaccination, the cost of a fully vaccinated child (including monovalent hepatitis B) is US
$2.19. Introduction of Hib conjugate vaccine increased annual costs four-fold, leading to 
costs per fully vaccinated child of US$8.81. The estimated total incremental cost for 2012–
2031 was US$2006 million after discounting at 3% per year.
Health Care Costs Avoided by Hib Conjugate Vaccination
Around 15% of the vaccine costs would be offset by health care cost savings due to reduced 
cases of Hib disease. This percentage varied considerably by state; in the Central region 
around a one-quarter of the vaccine costs were offset by health care costs (Table IV). Total 
costs avoided over the 2012–2031 period would be US$310 million after discounting at 3% 
per year. Around 77% (US$240 million) would be avoided by households, with the 
remaining US$70 million by the government.
Hib Conjugate Vaccine Cost-Effectiveness
From a government perspective, state-level cost-effectiveness ranged from US$192-US
$1033 per DALY averted after discounting costs and benefits at 3% per year. With the 
inclusion of household health care costs, cost-effectiveness ranged from US$155-US$939 
per discounted DALY averted. The vaccine would be most cost-effective in the Central and 
Eastern States (Figure 4). States with the highest percentage reductions in under-5 deaths 
were as diverse as Madhya Pradesh, Jharkhand, West Bengal, and Kerala.
Uncertainty and Scenario Analyses
For a 10% change in each parameter, in all states the parameter with the largest percent 
impact on the discounted cost per DALY averted was relative coverage (12%–17% effect 
across states), a parameter rarely included in cost-effectiveness studies of vaccines. In all 
states, the parameter with the second largest influence was vaccine dose price (11%–16% 
effect). The influence and rank of other parameters varied by state, but the incidence of Hib 
pneumonia deaths and the efficacy of the vaccine against Hib pneumonia had important 
effects (7%–14%) in all states.
A variety of assumptions, favorable and unfavorable to Hib conjugate vaccine introduction, 
were considered in scenario analysis (Figure 5). Costs per DALY averted ranged from a cost 
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saving scenario, in which health care cost savings are greater than the cost of the vaccine 
program itself, to an unfavorable scenario costing US$1830 per discounted DALY averted. 
Figure 5 shows the cost per DALY averted of the base case scenario (US$331) and the 
cumulative effect of introducing favorable and unfavorable assumptions in sequence. Hence, 
the most unfavorable scenario (US$1830) combines all unfavorable assumptions listed above 
the base case scenario, and the cost saving scenario combines all favorable assumptions 
listed below the base case scenario.
Discussion
Models of this kind cannot and do not seek to estimate the precise epidemiologic “truth” 
about the impact of a vaccine. Instead, they provide a framework for exploring the 
implications of a range of plausible scenarios or “futures,” recognizing that, even with a 
large body of accumulated (and forthcoming) clinical evidence, there will be inherent and 
unavoidable uncertainties in a population as large and diverse as India’s.
A large body of local epidemiologic evidence is available from India for many of the 
parameters considered in this model. Where information is lacking or uncertain, we have 
had to make assumptions. For example, “all-cause pneumonia” was used as a proxy when 
identifying risk-factors for “Hib pneumonia” and estimating access to care. Several 
assumptions also were required to generate plausible estimates of state-level variation. 
However, where significant uncertainties exist, we have varied them in scenario analysis to 
test the extent to which they have an important bearing on the results. Our scenario analysis 
explored the cumulative effect of adding a series of favourable and unfavorable assumptions 
in sequence. In our most unfavorable scenario, we assumed 50% of the base case incidence 
for Hib pneumonia, and the unadjusted incidence of 7 per 100 000 <5 years for Hib 
meningitis (less than one-third of the base case estimate). We also applied a 5% discount 
rate, 10% fewer outpatient visits and hospitalizations, 10% lower health care costs, lower 
vaccine efficacy (83% for 1 dose, 69% for 2 doses, 0% for 1 dose), no herd effect, delayed 
timing of vaccination, clustering of deaths in the unvaccinated population (relative 
coverage), 5% waning dose protection per year, and exclusion of all household health care 
cost savings. In spite of this extreme combination of unfavorable assumptions, the cost per 
DALY averted remained between 1 and 3 × gross domestic product (GDP) per capita, and 
would still be considered cost-effective according to WHO benchmarks.59 Nearly all other 
scenarios, including the base case scenario, are considered highly cost-effective with costs/
DALY below US$1410, which was the per capita GDP in India in 2010.60 The WHO 
thresholds have been widely debated,61 but the fact that all scenarios, even those with 
unfavorable combinations of assumptions, are within 3 times the GDP per capita, suggest 
that the vaccine would be good value for the Indian Government.
A state-level cost-effectiveness analysis of Hib conjugate vaccination was conducted in the 
State of Haryana using an earlier version of our model. With different estimates and 
assumptions for their base case scenario,62 the authors report a discounted cost per DALY 
averted from a government perspective of US$819, which is similar to our estimate for 
Haryana State (US$903).
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Investment in Hib conjugate vaccination would increase annual vaccine costs from US$42 
million to US$170 million. However, current government spending on vaccines is very low 
(around 2% of the national health budget)63 and US$8.81 per vaccinated child is still far less 
than other countries with similar economies spend on vaccines.64,65 In addition, we estimate 
that about 15% of the additional vaccine program costs would potentially be offset by health 
care cost savings. Because the Indian health system is dominated by a large private sector, 
health care costs are largely in the form of out-of-pocket costs, which often result in 
substantial financial burdens to households. It is estimated that more than 40% of Indian 
households have to borrow money or sell assets to cover hospital expenses.66 In our analysis, 
the costs avoided by households accounted for 77% of the total health care costs avoided.
Our evaluation supports nationwide introduction of Hib conjugate vaccination. It is 
encouraging that Hib conjugate vaccines have already been introduced in Tamil Nadu and 
Kerala, but we estimate that these states represent as little as 4% of the potential lives that 
could be saved each year in India. Hib conjugate vaccination would be most cost-effective in 
the Central and Eastern regions where there the vaccine has the greatest potential to reduce 
absolute numbers of deaths. Efforts should therefore be made to expedite nationwide 
introduction. The impact of Hib conjugate vaccination in India has already been 
demonstrated in a limited setting in India.67 Nonetheless, it will be important to continue 
adequate surveillance to monitor the impact of this vaccine as introduction scales up.
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Glossary
ALRI Acute lower respiratory infection
CFR Case fatality ratio
DALY Disability adjusted life year
DTP Diphtheria-tetanus-pertussis
GDP Gross domestic product
Hib Haemophilus influenzae type b
NFHS National Family Health Survey (also known as the Demographic and Health 
Survey or DHS)
NPNM Non-pneumonia-non-meningitis
WHO World Health Organization
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Figure 1. 
Simplified structure of the Hib disease burden model.
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Figure 2. 
Method for estimating state-level Hib pneumonia cases and deaths at ages 1–59 months.
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Figure 3. 
State-level coverage of DTP2 vaccination: underweight infants relative to all infants. DTP2 
coverage data from NFHS 2006.
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Figure 4. 
Impact and cost-effectiveness of Hib vaccination by State of India.
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Figure 5. 
Scenario analysis showing the cost per DALY averted for the base case scenario and the 
cumulative effect of introducing favourable and unfavorable assumptions in sequence. The 
plus symbol (+) indicates the sequential and cumulative addition of assumptions to the base 
case. These are either favorable to the vaccine (bottom half of chart) or unfavorable to the 
vaccine (top half of chart).
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